Objective To systematically review the effect and safety of bevacizumab as salvage treatment for Her-2 negative recurrent or metastatic breast cancer. Methods The stage III randomized controlled trials (RCTs) on chemotherapy plus bevacizumab vs. chemotherapy alone for Her-2 negative recurrent or metastatic breast cancer were collected from PubMed, EMbase, The Cochrane Library, SCI citation database and CBM. Conference abstracts in ASCO and ESMO during last three years, NCCN guideline (2012), as well as relevant Chinese journals were also retrieved manually. The retrieved literature was published from the inception of databases to February 2012. Two reviewers independently screened the literature according to inclusion and exclusion criteria, evaluated and cross-checked methodological quality, and resolved discrepancy by discussion or according to expert opinion. Then meta-analysis was conducted using STATA SE 12.0 software. Results Of 132 articles collected, a total of 4 RCTs involving 3 131 patients were included. The results of meta-analyses showed that: compared with chemotherapy alone, bevacizumab plus chemotherapy could improve the progression-free survival (PFS) for patients with Her-2 negative breast cancer (HR=0.67, 95%CI 0.57 to 0.79, P=0.001), but it could not prolong the overall survival (OS) (HR=0.92, 95%CI 0.82 to 1.02, P=0.121). Adverse effects such as hypertension, proteinuria and bleeding significantly increased in the bevacizumab group, but no statistical significance was found in thrombo-embolic event, neutropenia and sensory neuropathy between the two groups. Conclusion Bevacizumab can improve PFS rather than OS for patients with Her-2 negative recurrent or metastatic breast cancer, and it increases the Grade 3 to 4 adverse effects. It is necessary to identify the best indications of bevacizumab as salvage treatment for breast cancer.
Objective To study the expressions of human ether-a-go-go related gene (HERG) in CD1 mice gallbladder and interstitial cells of Cajal (ICC) and explore their possible implications. Methods The expression of HERG protein in gallbladder tissue slices obtained from CD1 mice was detected by immunohistochemistry method. The expression of HERG mRNA in gallbladder tissue was detected by reverse transcription (RT)-PCR. The production of HERG protein was confirmed in the CD1 mice gallbladder by Western blot. Enzymatically dispersed cells were identified as ICC using the specific ICC marker c-kit antibody, and the double positive cells of c-kit and HERG were observed by laser passing confocal microscope. Results HERG was present in the CD1 mice gallbladder tissues for the yellow or buffy positive reaction. At the same time, the expression of mRNA specific for the HERG gene and production of HERG protein in the CD1 mice gallbladder tissues were indicated by RT-PCR and Western blot analysis, respectively. Using double labeling of anti-c-kit and anti-HERG, the double positive cells of c-kit and HERG were observed in the CD1 mice ICC by laser passing confocal microscope. Conclusion The study demonstrates that HERG is present in the CD1 mice gallbladder tissues and ICC, which is likely related to the pacemaking activity of ICC.
Lung cancer is the most common cancer and the leading cause of cancer-related death in China. Early screening of lung cancer proves to be effective in improving its prognosis. The National Comprehensive Cancer Network (NCCN) has updated and released version 2, 2022 NCCN clinical practice guidelines for lung cancer screening in July, 2022. Based on high-quality clinical evidence and the latest research progress, the guidelines have developed and updated criteria for lung cancer screening which have been widely recognized by clinicians around the world. Compared with Chinese lung cancer screening guidelines, this article will interpret the updated content of the brand new 2022 NCCN screening guidelines, providing some reference for the current lung cancer screening practice in our country.
ObjectiveTo compare the clinical effects of segmentectomy and lobectomy for ≤2 cm lung adenocarcinoma with micropapillary and solid subtype negative by intraoperative frozen sections.MethodsThe patients with adenocarcinoma who received segmentectomy or lobectomy in multicenter from June 2020 to March 2021 were included. They were divided into two groups according to a random number table, including a segmentectomy group (n=119, 44 males and 75 females with an average age of 56.6±8.9 years) and a lobectomy group (n=115, 43 males and 72 females with an average of 56.2±9.5 years). The clinical data of the patients were analyzed.ResultsThere was no significant difference in the baseline data between the two groups (P>0.05). No perioperative death was found. There was no statistical difference in the operation time (111.2±30.0 min vs. 107.3±34.3 min), blood loss (54.2±83.5 mL vs. 40.0±16.4 mL), drainage duration (2.8±0.6 d vs. 2.6±0.6 d), hospital stay time (3.9±2.3 d vs. 3.7±1.1 d) or pathology staging (P>0.05) between the two groups. The postoperative pulmonary function analysis revealed that the mean decreased values of forced vital capacity and forced expiratory volume in one second percent predicted in the segmentectomy group were significantly better than those in the lobectomy group (0.2±0.3 L vs. 0.4±0.3 L, P=0.005; 0.3%±8.1% vs. 2.9%±7.4%, P=0.041).ConclusionSegmentectomy is effective in protecting lungs function, which is expected to improve life quality of patients.